Disparities in the presence of driver mutations and response to tyrosine kinase inhibitors in young patients with lung cancer

被引：0
|
作者：
Edwards, Kyle
Rose, Brandon
Lopes, Gilberto
Rodriguez, Estelamari
Olazagasti, Coral
机构：
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2024年 / 33卷 / 09期
关键词：
D O I：
10.1158/1538-7755.DISP24-A106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A106
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Primary and Secondary Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
    Simasi, Jacinta
    Schubert, Andreas
    Oelkrug, Christopher
    Gillissen, Adrian
    Nieber, Karen
    ANTICANCER RESEARCH, 2014, 34 (06) : 2841 - 2850
  • [42] EGFR tyrosine kinase inhibitors in squamous cell lung cancer
    Hirsch, Fred R.
    Herbst, Roy S.
    Gandara, David R.
    LANCET ONCOLOGY, 2015, 16 (08): : 872 - 873
  • [43] Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
    Suda, Kenichi
    Mitsudomi, Tetsuya
    CELLS, 2021, 10 (07)
  • [44] EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells
    Han, Weidong
    Pan, Hongming
    Chen, Yan
    Sun, Jie
    Wang, Yanshan
    Li, Jing
    Ge, Weiting
    Feng, Lifeng
    Lin, Xiaoying
    Wang, Xiaojia
    Wang, Xian
    Jin, Hongchuan
    PLOS ONE, 2011, 6 (06):
  • [45] Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival
    Suidan, Anna May
    Roisman, Laila
    Rozenblum, Anna Belilovski
    Ilouze, Maya
    Dudnik, Elizabeth
    Zer, Alona
    Peled, Nir
    JOURNAL OF GLOBAL ONCOLOGY, 2019, 5 : 1 - 8
  • [46] Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement but Better Survival
    Suidan, A.
    Ilouze, M.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2281 - S2281
  • [47] Lung Cancer in Young Patients: Higher Rate of Driver Mutations, Brain Involvement and Better Survival
    Suidan, Anna
    Ilouze, Maya
    Peled, Nir
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1526 - S1526
  • [48] Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review
    Leporati, Rita
    Auclin, Edouard
    Morchon, Daniel
    Ferriol-Galmes, Miquel
    Laguna, Juan Carlos
    Gorria, Teresa
    Teixido, Cristina
    Aranzazu Amores, Maria
    Ambrosini, Paolo
    Isla, Dolores
    Lo Russo, Giuseppe
    Mezquita, Laura
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [49] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China
    Xu, Jianlin
    Zhang, Yanwei
    Jin, Bo
    Chu, Tianqing
    Dong, Xue
    Yang, Haitang
    Wu, Dan
    Lou, Yuqing
    Zhang, Xueyan
    Wang, Huiming
    Han, Baohui
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (06) : 1325 - 1330
  • [50] Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
    Peng, Liang
    Song, Zhi-Gang
    Jiao, Shun-Chang
    SCIENTIFIC REPORTS, 2014, 4
12345